Obesity, smoking, and poor sleep raise risk of myeloma precursor
Obesity, a history of heavy smoking, and limited sleep are risk factors for developing monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to…
News
STAR-LLD combo showing potential for multiple myeloma in clinical trial
STAR-LLD, a continuous infusion of low-dose lenalidomide into the blood, shows the potential to be a better treatment choice than Revlimid, an oral formulation…
AstraZeneca to add CAR T-cell therapy to pipeline with Gracell buy
AstraZeneca is set to buy Gracell Biotechnologies in a deal worth up to $1.2 billion that would add GC012F — an experimental dual-targeting…
Darzalex Faspro combo benefits patients new to MM and transplant
Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to…
Elrexfio approved for hard-to-treat multiple myeloma patients in Europe
The European Commission has granted conditional marketing authorization to Elrexfio (elranatamab) to treat adults with multiple myeloma who received at least prior…
New cases of myeloma rose in US, mostly in young Hispanic women
A study has observed a rise in the number of new cases of myeloma in both men and women in the U.S. since the…
Blenrep works better than Darzalex as early therapy, trial data show
When added to a second-line combination therapy, Blenrep (belantamab mafodotin) — developed by GlaxoSmithKline (GSK) for relapsed or treatment-resistant …
FDA delays its decision on earlier Abecma treatment for RRMM
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to…
1st patient dosed in Phase 1 trial of triple-target treatment ISB 2001
The first multiple myeloma patient has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of ISB 2001, Ichnos…
Foundation awards $21M in grants for multicenter myeloma research
Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more effective treatment options for newly…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL